AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACL

ACL - AUSTRALIAN CLINICAL LABS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.67
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.03

21 Mar
2025

-0.050

OPEN

$3.07

-1.62%

HIGH

$3.12

1,803,243

LOW

$3.03

TARGET
$3.65 20.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
ACL: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 12.0 18.7 xxx
DPS (cps) xxx 12.0 12.5 xxx
EPS Growth xxx - 32.8% 55.2% xxx
DPS Growth xxx - 14.3% 4.2% xxx
PE Ratio xxx N/A 16.2 xxx
Dividend Yield xxx N/A 4.1% xxx
Div Pay Ratio(%) xxx 99.8% 67.0% xxx

Dividend yield today if purchased 3 years ago: 2.24%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.96

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 3c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx12.0
DPS All xxxxxxxxxxxxxxx12.0
Sales/Revenue xxxxxxxxxxxxxxx689.7 M
Book Value Per Share xxxxxxxxxxxxxxx89.4
Net Operating Cash Flow xxxxxxxxxxxxxxx159.6 M
Net Profit Margin xxxxxxxxxxxxxxx3.47 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx13.68 %
Return on Invested Capital xxxxxxxxxxxxxxx6.22 %
Return on Assets xxxxxxxxxxxxxxx4.08 %
Return on Equity xxxxxxxxxxxxxxx13.68 %
Return on Total Capital xxxxxxxxxxxxxxx11.66 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx133.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx105 M
Long Term Debt xxxxxxxxxxxxxxx204 M
Total Debt xxxxxxxxxxxxxxx309 M
Goodwill - Gross xxxxxxxxxxxxxxx159 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx27 M
Price To Book Value xxxxxxxxxxxxxxx2.81

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.5 M
Capex % of Sales xxxxxxxxxxxxxxx0.94 %
Cost of Goods Sold xxxxxxxxxxxxxxx551 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx82 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

27/02/2025

1

Buy

$3.80

25.41%

 Australian Clinical Labs reported first half earnings that suggest it is on track to meet FY25 expectations, with guidance reiterated for EBIT of $65-73m.

Ord Minnett updates EBIT forecasts to $71m and assumes revenue growth will slow to 6.6% in the second half amid relatively flat operating expenditure.

Upside is envisaged if the share buyback activity accelerates. Buy rating retained. Target edges down to $3.80 from $3.90.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 12.50 cents and EPS of 18.20 cents.
Ord Minnett forecasts a full year FY26 dividend of 14.30 cents and EPS of 21.50 cents.

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

ACL STOCK CHART

FNArena News on ACL

1
Rudi’s View: To Sell Or Not To Sell

Mar 06 2025 - Rudi's View
2
FNArena Corporate Results Monitor – 27-02-2025

Feb 27 2025 - Australia
3
Rudi Interviewed: Turning Laggards Into Winners

Feb 17 2025 - Rudi's View
4
Next Week At A Glance -17-21 Feb 2025

Feb 14 2025 - Weekly Reports
5
Rudi’s View: Hope Trumps Uncertainties

Feb 12 2025 - Rudi's View

Latest Healthcare services News

1
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
2
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
3
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
4
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
5
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
6
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
7
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
8
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
9
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
10
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps